Viela Bio, Mitsubishi Tanabe Pharma enter strategic collaboration
Viela Bio and Mitsubishi Tanabe Pharma announced a collaboration focused on the development and commercialization of inebilizumab - Viela's humanized anti-CD19 monoclonal antibody - in nine Asia regions for neuromyelitis optica spectrum disorder, as well as other potential future indications. Under terms of the collaboration, Viela will receive an up-front licensing fee of $30M as well as additional payments contingent on certain development and commercial milestones, plus payments based, in part, on sales revenue. MTPC will be responsible for leading development and commercialization of inebilizumab in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, Philippines, Singapore, and Taiwan. The U.S. FDA recently accepted for review Viela's Biologics License Application for inebilizumab for the treatment of NMOSD.